

### DAFTAR PUSTAKA

- Bedouch, P., Allenet, B., Grass, A., Labarère, J., Brudieu, E., Bosson, J.-L., Calop, J., 2009. Drug-related problems in medical wards with a computerized physician order entry system. *J. Clin. Pharm. Ther.* 34, 187–195. <https://doi.org/10.1111/j.1365-2710.2008.00990.x>
- Betônico, C.C.R., Titan, S.M.O., Correa-Giannella, M.L.C., Nery, M., Queiroz, M., 2016. Management of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic control. *Clinics* 71, 47–53. [https://doi.org/10.6061/clinics/2016\(01\)08](https://doi.org/10.6061/clinics/2016(01)08)
- Chang, P.-Y., Chien, L.-N., Lin, Y.-F., Wu, M.-S., Chiu, W.-T., Chiou, H.-Y., 2016. Risk factors of gender for renal progression in patients with early chronic kidney disease. *Medicine (Baltimore)* 95. <https://doi.org/10.1097/MD.0000000000004203>
- Chow, F.-S., Jusko, W.J., 2004. Immunosuppressive Interactions among Calcium Channel Antagonists and Selected Corticosteroids and Macrolides Using Human whole Blood Lymphocytes. *Drug Metab. Pharmacokinet.* 19, 413–421.
- Cipolle, R., Strand, L., Morley, P., 1998. *Pharmaceutical Care Practice: The Patient Centered Approach to Medication Management*, 3rd ed. McGraw-Hill, New York.
- Cooper-DeHoff, R.M., 2008. Thiazide Induced Dysglycemia – It’s Time To Take Notice. *Expert Rev. Cardiovasc. Ther.* 6, 1291–1294. <https://doi.org/10.1586/14779072.6.10.1291>
- Depkes RI, 2009. *Sistem Kesehatan Nasional*. Diperoleh tanggal 19 Juli 2018 dari <http://www.depkes.go.id>.
- Duru, O.K., Li, S., Jurkovitz, C., Bakris, G., Brown, W., Chen, S.-C., Collins, A., Klag, M., McCullough, P.A., McGill, J., Narva, A., Pergola, P., Singh, A., Norris, K., 2008. Race and Sex Differences in Hypertension Control in CKD: Results From the Kidney Early Evaluation Program (KEEP). *Am. J. Kidney Dis. Off. J. Natl. Kidney Found.* 51, 192–198. <https://doi.org/10.1053/j.ajkd.2007.09.023>
- Farooq, V., Hegarty, J., Chandrasekar, T., Lamerton, E.H., Mitra, S., Houghton, J.B., Kalra, P.A., Waldek, S., O’Donoghue, D.J., Wood, G.N., 2004. Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. *Am. J. Kidney Dis. Off. J. Natl. Kidney Found.* 43, 531–537.
- Fitriani, R., 2009. *Identifikasi Drug Related Problems (DPRs) Kategori Kontraindikasi Dan Ketidaktepatan Dosis Obat Pada Pasien Hipertensi Di Instalasi Rawat Inap RSUD Dr. Moewardi Surakarta Tahun 2007*. Skripsi.
- Fraser, S.D.S., Roderick, P.J., May, C.R., McIntyre, N., McIntyre, C., Fluck, R.J., Shardlow, A., Taal, M.W., 2015. The burden of comorbidity in people with chronic kidney disease stage 3: a cohort study. *BMC Nephrol.* 16. <https://doi.org/10.1186/s12882-015-0189-z>
- Goicoechea, M., de Vinuesa, S.G., Verdalles, U., Ruiz-Caro, C., Ampuero, J., Rincón, A., Arroyo, D., Luño, J., 2010. Effect of Allopurinol in Chronic

- Kidney Disease Progression and Cardiovascular Risk. *Clin. J. Am. Soc. Nephrol.* CJASN 5, 1388–1393. <https://doi.org/10.2215/CJN.01580210>
- Herchuelz, A., Derenne, F., Deger, F., Juvent, M., Van Ganse, E., Staroukine, M., Verniory, A., Boeynaems, J.M., Douchamps, J., 1989. Interaction between nonsteroidal anti-inflammatory drugs and loop diuretics: modulation by sodium balance. *J. Pharmacol. Exp. Ther.* 248, 1175–1181.
- Hill, N.R., Fatoba, S.T., Oke, J.L., Hirst, J.A., O’Callaghan, C.A., Lasserson, D.S., Hobbs, F.D.R., 2016. Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. *PLoS ONE* 11. <https://doi.org/10.1371/journal.pone.0158765>
- Hughes, S., Szeki, I., Nash, M.J., Thachil, J., 2014. Anticoagulation in chronic kidney disease patients—the practical aspects. *Clin. Kidney J.* 7, 442–449. <https://doi.org/10.1093/ckj/sfu080>
- Jain, N., Hedayati, S.S., Sarode, R., Banerjee, S., Reilly, R.F., 2013. Antiplatelet Therapy in the Management of Cardiovascular Disease in Patients with CKD: What Is the Evidence? *Clin. J. Am. Soc. Nephrol.* 8, 665–674. <https://doi.org/10.2215/CJN.06790712>
- Jamal, I., Amin, F., Jamal, A., Saeed, A., 2015. Pharmacist’s Interventions In Reducing The Incidences Of Drug Related Problems In Any Practice Setting. *International Current Pharmaceutical Journal*, 349.
- Johnston, S., 2016. Symptom Management in Patients with Stage 5 CKD Opting for Conservative Management. *Healthcare* 4. <https://doi.org/10.3390/healthcare4040072>
- Katzung, B., 2002. *Farmakologi Dasar dan Klinik*, Keenam. ed. Jakarta: Penerbit Salemba Medika.
- KDIGO, 2012. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. *Kidney inter., Suppl.* 2012;2: 279–335.
- KDOQI, 2012. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD. 2012;60(5):850-886.
- Khan, Y.H., Sarriff, A., Adnan, A.S., Khan, A.H., Mallhi, T.H., 2016. Chronic Kidney Disease, Fluid Overload and Diuretics: A Complicated Triangle. *PLoS ONE* 11. <https://doi.org/10.1371/journal.pone.0159335>
- Lacy, C.F., Armstrong, L.L., Goldman, M.P., Lance, L.L., 2010. *Drug Information Handbook with International Trade Names Index*, 18th ed. Lexi-Comp Inc., United State of America.
- Levey, A.S., Corresh, J., Kausz, A., Levin, A., 2002. *National Kidney Foundation-Kidney Disease Outcome Quality Initiative (NKF-K/DOQI), K/DOQI Clinical Practice Guideline for Chronic Kidney Disease: Evaluation, Classification, and Stratification*.
- Macdougall, I.C., 2017. Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions. *Clin. Kidney J.* 10, i16–i24. <https://doi.org/10.1093/ckj/sfx043>
- Mahmoud, M., 2008. *Drug Therapy Problems and Quality of Life in Patients with Chronic Kidney Disease*. Metodologi Penelitian Kesehatan. Yogyakarta: PT. Rineka Cipta, Universiti Sains Malaysia. Notoatmodjo, S. (2002).

- Mayes, P., 2003. *Pengangkutan dan Penyimpanan Lipid* dalam: Murray et al, editor : Biokimia Harper., 25th ed. EGC. Hal 254, 260-262, Jakarta.
- Mikolasevic, I., Žutelija, M., Mavrinac, V., Orlic, L., 2017. Dyslipidemia in patients with chronic kidney disease: etiology and management. *Int. J. Nephrol. Renov. Dis.* 10, 35–45. <https://doi.org/10.2147/IJNRD.S101808>
- Murtagh, F.E.M., Addington-Hall, J., Higginson, I.J., 2007. The prevalence of symptoms in end-stage renal disease: a systematic review. *Adv. Chronic Kidney Dis.* 14, 82–99. <https://doi.org/10.1053/j.ackd.2006.10.001>
- O'Connor, N.R., Corcoran, A.M., 2012. End-Stage Renal Disease: Symptom Management and Advance Care Planning. *Am. Fam. Physician* 85, 705–710.
- Patel, P.S., Rana, D.A., Suthar, J.V., Malhotra, S.D., Patel, V.J., 2014. A study of potential adverse drug-drug interactions among prescribed drugs in medicine outpatient department of a tertiary care teaching hospital. *J. Basic Clin. Pharm.* 5, 44–48. <https://doi.org/10.4103/0976-0105.134983>
- PERNEFRI, 2014. *7th Report of Indonesian Renal Registry*, Program Indonesian Renal Registry.
- Prakash, S., O'Hare, A.M., 2009. Interaction of Aging and CKD. *Semin. Nephrol.* 29, 497–503. <https://doi.org/10.1016/j.semnephrol.2009.06.006>
- Price, S.A., Wilson, L.M.C., 2006. *Patofisiologi : Konsep Klinis Proses-Proses Penyakit*, 6th ed. EGC, Jakarta.
- Purnomo, B.B., 2003. *Dasar-Dasar Urologi, Kedua*. ed. Sagung Seto, Jakarta.
- Rao, G.A., Mann, J.R., Shoaibi, A., Bennett, C.L., Nahhas, G., Sutton, S.S., Jacob, S., Strayer, S.M., 2014. Azithromycin and Levofloxacin Use and Increased Risk of Cardiac Arrhythmia and Death. *Ann. Fam. Med.* 12, 121–127. <https://doi.org/10.1370/afm.1601>
- Ruths, S., Viktil, K., Blix, H., 2007. Classification of drug-related problems. *The Journal of the Norwegian Medical Association*, 127, 3.
- Salerno, F.R., Parraga, G., McIntyre, C.W., 2017. Why Is Your Patient Still Short of Breath? Understanding the Complex Pathophysiology of Dyspnea in Chronic Kidney Disease. *Semin. Dial.* 30, 50–57. <https://doi.org/10.1111/sdi.12548>
- Seto, S., Nita, Y., Triana, L., 2004. *Manajemen Farmasi*. Airlangga University Press, Surabaya.
- Sharaf El Din, U.A.A., Salem, M.M., Abdulazim, D.O., 2016. Stop chronic kidney disease progression: Time is approaching. *World J. Nephrol.* 5, 258–273. <https://doi.org/10.5527/wjn.v5.i3.258>
- Shargel, L., Wu-Pong, S., B.C.Yu, A., 2012. *Biofarmasetika dan Farmakokinetika Terapan*, Edisi Kelima. ed. Airlangga University Press, Surabaya.
- Stevens, L.A., Li, S., Wang, C., Huang, C., Becker, B.N., Bomback, A.S., Brown, W.W., Burrows, N.R., Jurkovitz, C.T., McFarlane, S.I., Norris, K.C., Shlipak, M., Whaley-Connell, A.T., Chen, S.-C., Bakris, G.L., McCullough, P.A., 2010. Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). *Am. J. Kidney Dis. Off. J. Natl. Kidney Found.* 55, S23-33. <https://doi.org/10.1053/j.ajkd.2009.09.035>

- Sudoyo, A.W., Simadibrata K., M., Setiyohadi, B., Alwi, I., 2009. *Ilmu Penyakit Dalam*, Kelima. ed, Jilid II. Interna Publishing, Jakarta.
- Suwitra, K., 2009. *Penyakit Ginjal Kronik*. In: Aru W Sudoyo, Kelima. ed, Jilid 2. *Buku Ajar Ilmu Penyakit Dalam*, Jakarta: Interna Publishing.
- Syarif, A., Estuningtyas, A., Setiawati, A., Muchtar, A., 2007. *Farmakologi dan Terapi*, 5th ed. Departemen Farmakologi dan Terapeutik Fakultas Kedokteran Universitas Indonesia, Jakarta.
- Tatro, D., 2001. *Drug Interaction Facts*, 5th ed. St Louis Missouri: A Wolters Kluwer Company, United State of America.
- T.Dipiro, J., G.Wells, B., L.Schwinghammer, T., V.Dipiro, C., 2015. *Pharmacotherapy Handbook*, Ninth Edition. ed. McGraw-Hill Education.
- Telles-Correia, D., Barbosa, A., Cortez-Pinto, H., Campos, C., Rocha, N.B.F., Machado, S., 2017. Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity. *World J. Gastrointest. Pharmacol. Ther.* 8, 26–38. <https://doi.org/10.4292/wjgpt.v8.i1.26>
- Thomas, R., Kanso, A., Sedor, J.R., 2008. Chronic Kidney Disease and Its Complications. *Prim. Care* 35, 329–vii. <https://doi.org/10.1016/j.pop.2008.01.008>
- Trisna, A.P., 2015. *Evaluasi Drug Related Problem Pada Pasien Gagal Ginjal Kronik di Rumah Sakit Pelabuhan Jakarta Utara*. Universitas Islam Negeri Syarif Hidayatullah, Jakarta. Skripsi
- Trumic, E., Pranjin, N., Begic, L., Bečić, F., 2012. Prevalence of Polypharmacy and Drug Interaction Among Hospitalized Patients: Opportunities and Responsibilities in Pharmaceutical Care. *Mater. Socio-Medica* 24, 68–72. <https://doi.org/10.5455/msm.2012.24.68-72>
- Wagner, L.-A., Tata, A.L., Fink, J.C., 2015. Patient Safety Issues in CKD. *Am. J. Kidney Dis. Off. J. Natl. Kidney Found.* 66, 159–169. <https://doi.org/10.1053/j.ajkd.2015.02.343>
- Wanner C, T.M., 2013. Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members KDIGO clinical practice guideline for lipid management in chronic kidney disease.
- Zhang, J., Huang, C., Li, Y., Chen, J., Shen, F., Yao, Q., Qian, J., Bao, B., Yao, X., 2013. Health-related quality of life in dialysis patients with constipation: a cross-sectional study. *Patient Prefer. Adherence* 7, 589–594. <https://doi.org/10.2147/PPA.S45471>